The proposed Bill No. 5485 aims to establish a captive insurance company in Connecticut dedicated to the bulk purchase and distribution of glucagon-like peptide-1 (GLP-1) prescription drugs for individuals suffering from obesity. The bill includes an appropriation of ten million dollars from the General Fund for the fiscal year ending June 30, 2026, to support the operations of this captive insurance company. The company will focus on acquiring GLP-1 receptor antagonist drugs from manufacturers and distributing them to qualifying individuals who meet a means-tested qualification process and are unable to obtain these medications through their health insurers.

The bill seeks to amend title 38a of the general statutes to facilitate this initiative, which is designed to improve access to essential obesity treatment medications for those in need. By establishing this program, the bill aims to address the barriers faced by individuals who require these prescription drugs but cannot afford them or obtain them through their existing health insurance coverage.